Close Menu
    Facebook X (Twitter) Instagram Pinterest YouTube LinkedIn TikTok
    TopBuzzMagazine.com
    Facebook X (Twitter) Instagram Pinterest YouTube LinkedIn TikTok
    • Home
    • Movies
    • Television
    • Music
    • Fashion
    • Books
    • Science
    • Technology
    • Cover Story
    • Contact
      • About
      • Amazon Disclaimer
      • Terms and Conditions
      • Privacy Policy
      • DMCA / Copyrights Disclaimer
    TopBuzzMagazine.com
    Home»Science»Leukaemia drug shows promise at treating breast cancer once it
    Science

    Leukaemia drug shows promise at treating breast cancer once it

    By AdminApril 2, 2023
    Facebook Twitter Pinterest LinkedIn Tumblr Email
    Leukaemia drug shows promise at treating breast cancer once it

    A micrograph of oestrogen-receptor positive breast cancer tissue, showing slowly dividing cancer cells (red) that resist treatment, the cells’ nuclei (blue) and rapidly dividing cancer cells (green)

    Dana-Farber Harvard Cancer Center at Massachusetts General Hospital/NATIONAL CANCER INSTITUTE/SCIENCE PHOTO LIBRARY

    A repurposed leukaemia drug may be able to stop the most common type of breast cancer from causing tumours elsewhere in the body, according to a study in mice. The drug can cause side effects, however, and there is no way of telling who is most at risk of their breast cancer spreading, which may limit the treatment’s use as a preventative measure for secondary cancer.

    Frances Turrell at the Institute of Cancer Research in the UK and her colleagues induced oestrogen-receptor positive (ER+) breast cancer in mice. This is the most common type of breast cancer in humans, accounting for up to 80 per cent of cases, and usually occurs in people over the age of 50.

    ER+ breast cancer frequently recurs several years after seemingly successful treatment. This is because the cells can move to other sites in the body prior to treatment and cannot be detected before the therapy is initiated, says Turrell. “These cells essentially stay dormant and then something may trigger them to reawaken them.”

    Advertisement

    To learn more, the researchers gave young mice – aged 8 to 10 weeks – and older mice – aged 9 to 18 months – ER+ positive breast cancer. The mice, which were all female, weren’t treated for these tumours. Between two and five weeks later, nearly all had cancer cells at secondary sites.

    In the young mice, these secondary site cancer cells didn’t divide into tumours, while in the older mice the cells were more likely to develop into tumours, which mainly grew in the animals’ lungs.

    The researchers then found that tumour growth in the older mice was linked to an increase in the growth factor PDGF-C in the lungs, which occurred less in the younger mice.

    In both people and mice, PDGF-C levels increase in the lungs with age, which may trigger an environment that stimulates secondary cancer cells to divide, says Turrell.

    According to Clare Isacke at the Institute of Cancer Research, higher PDGF-C levels may be linked with a weakened immune system.

    In another part of the experiment, the researchers partly blocked tumour growth in the older mice after the cancerous cells had spread to the animals’ lungs. This was done by inhibiting PDGF-C using the drug imatinib, which is widely given to people with chronic myeloid leukaemia.

    Imatinib inhibited the growth rate of the mice’s secondary tumours, but some lesions did still form, says Turrell.

    Although this may have potential for use in people, there is no way to predict whose ER+ breast cancer may later recur elsewhere in their body, she says.

    Imatinib has side effects, such as stomach pain and fatigue. “You don’t want to be treating someone who won’t actually experience a relapse,” says Isacke.

    The researchers now plan to repeat this experiment in mice using a drug that has a more targeted effect on PDGF-C levels.

    Suzanne Wardell at Duke University, North Carolina, says the study highlights the need to better understand the environmental factors in the body that cause a secondary tumour to grow. “Further work is needed to determine the overall general applicability of the findings to human cancer treatment,” she says.

    Article amended on 15 March 2023

    This article has been changed to correct the sex of the mice in the experiment.

    Topics:

    Read The Full Article Here

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

    Related Posts

    Failed Soviet probe will soon crash to Earth – and we don’t know where

    May 9, 2025

    After 170 years, Thoreau’s river observations inform our changing climate

    May 8, 2025

    World’s first silicon-based quantum computer is small enough to plug into a regular power socket

    May 7, 2025

    Nothing is stronger than quantum connections – and now we know why

    May 7, 2025

    Astronomers observe the cooling process of a young stellar object following an accretion burst

    May 6, 2025

    ‘Titanic: The Digital Resurrection’ documentary sheds light on night ship sank

    May 6, 2025
    popular posts

    Watch out for comet SW3, which might cause a meteor

    Gigi Hadid and Leonardo DiCaprio Seen In Milan But Are

    Mayans M.C. Renewed for Season 5

    Limp Bizkit’s Fred Durst Seeking Huge Sum in UMG Royalties Suit

    Successful hypothermia in nonhuman primate paves the way for future

    Prime Day Is Your Chance to Get a NuFACE on

    “Songs from the Reading Room” by New Zealander Arun O’Connor

    Categories
    • Books (3,212)
    • Cover Story (2)
    • Events (18)
    • Fashion (2,381)
    • Interviews (41)
    • Movies (2,511)
    • Music (2,789)
    • News (153)
    • Science (4,362)
    • Technology (2,505)
    • Television (3,234)
    • Uncategorized (932)
    Archives
    Facebook X (Twitter) Instagram Pinterest YouTube Reddit TikTok
    © 2025 Top Buzz Magazine. All rights reserved. All articles, images, product names, logos, and brands are property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Terms of Use and Privacy Policy.

    Type above and press Enter to search. Press Esc to cancel.

    We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
    Do not sell my personal information.
    Cookie SettingsAccept
    Manage consent

    Privacy Overview

    This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
    Necessary
    Always Enabled
    Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
    CookieDurationDescription
    cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
    cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
    cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
    cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
    cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
    viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
    Functional
    Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
    Performance
    Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
    Analytics
    Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
    Advertisement
    Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
    Others
    Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
    SAVE & ACCEPT